Low Alkaline Phosphatase: Recognizing Clinical Consequences

Alkaline phosphatase (ALP) is a ubiquitous enzyme with several isoforms, playing a critical role in bone mineralisation, liver function, and intestinal absorption. While high ALP levels are routinely investigated for liver disease, cholestasis, or bone disorders, low ALP is often dismissed as clinically insignificant. However, a growing understanding of its physiological roles highlights that persistently low ALP can be a diagnostic clue for several conditions, most notably hypophosphatasia (HPP).

HPP is an inherited metabolic disorder caused by mutations in the ALPL gene, which encodes the tissue-nonspecific alkaline phosphatase (TNSALP) enzyme. This enzyme is crucial for bone and tooth mineralisation, as it hydrolyses pyrophosphate, an inhibitor of mineralisation. Reduced TNSALP activity leads to an accumulation of its substrates, including inorganic pyrophosphate (PPi) and pyridoxal 5'-phosphate (PLP), resulting in defective mineralisation. The clinical spectrum of HPP is broad, ranging from severe, often fatal, perinatal forms to milder adult forms characterised by osteomalacia, recurrent fractures, and premature tooth loss.

Recognising the Clinical Spectrum

The presentation of HPP varies significantly with age and severity. Perinatal HPP, the most severe form, manifests with profound skeletal hypomineralisation, respiratory failure, and often leads to death shortly after birth. Infantile HPP presents within the first six months of life with rickets, craniosynostosis, and failure to thrive. Childhood HPP typically involves rickets, short stature, and premature loss of deciduous teeth (often before age five) due to cementum hypoplasia. Adult HPP, the most common form, can be subtle, presenting with chronic bone pain, stress fractures, pseudofractures, and chondrocalcinosis. Odontohypophosphatasia, a milder variant, primarily affects dental health, causing premature tooth exfoliation without significant skeletal involvement.

Beyond HPP, other conditions can also cause low ALP. These include severe malnutrition, zinc deficiency, magnesium deficiency, hypothyroidism, pernicious anaemia, and certain drug therapies, such as those with bisphosphonates or glucocorticoids. While these causes are generally more common, the specific clinical context, particularly the presence of skeletal or dental symptoms, helps differentiate them from HPP. For instance, a patient presenting with unexplained recurrent fractures and persistently low ALP should prompt consideration of HPP, even in the absence of a clear family history.

Diagnostic evaluation for suspected HPP involves measuring serum ALP levels, which are typically below the age- and sex-adjusted reference range. Confirmation often requires genetic testing for ALPL mutations and measurement of TNSALP substrates, such as plasma PLP and urine phosphoethanolamine (PEA). Elevated levels of these substrates support the diagnosis. Early recognition is critical, as enzyme replacement therapy with asfotase alfa is available for patients with paediatric-onset HPP, demonstrating improvements in skeletal mineralisation, motor function, and respiratory status.

Clinical Implications of Low ALP

The under-recognition of low alkaline phosphatase as a clinically significant marker represents a missed opportunity for early diagnosis and intervention in conditions like hypophosphatasia. General practitioners and specialists alike, particularly endocrinologists, rheumatologists, and paediatricians, should integrate persistently low ALP into their diagnostic algorithms. Dismissing a low ALP value as an isolated anomaly, especially in the presence of non-specific symptoms such as chronic bone pain or recurrent fractures, delays appropriate management and can lead to significant morbidity.

The availability of enzyme replacement therapy for paediatric-onset HPP underscores the importance of timely diagnosis. Asfotase alfa, a recombinant human TNSALP, has demonstrated efficacy in improving skeletal mineralisation and functional outcomes in affected children. This therapeutic option shifts HPP from a purely supportive management approach to one with disease-modifying potential. Therefore, the industry has a clear incentive to support educational initiatives that raise awareness of low ALP and its implications, potentially expanding the diagnosed patient population eligible for treatment.

For patients, improved diagnostic vigilance means a shorter diagnostic odyssey and access to targeted therapies that can mitigate the severe consequences of HPP. This includes preventing debilitating fractures, improving mobility, and enhancing quality of life. The challenge lies in overcoming the ingrained clinical habit of primarily focusing on elevated enzyme levels. Incorporating low ALP into routine differential diagnoses, particularly in paediatric and adult patients presenting with unexplained skeletal or dental issues, is a straightforward step that could significantly improve patient outcomes and reduce the long-term burden of these rare diseases.